12 November 2020 - Angelini Pharma and Sunovion Pharmaceutical Europe announced today the EMA approval for Latuda (lurasidone), with the indication ...
5 November 2020 - Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before in Europe. ...
16 October 2020 - EMA has recommended granting a marketing authorisation in the European Union for Oxlumo (lumasiran) for the ...
16 October 2020 - Data further reinforce the well-established safety profile of Dupixent in adult and adolescent atopic dermatitis patients. ...
23 September 2020 - Eisai announced that it has received a positive opinion from the EMA’s CHMP on the license extension ...
21 September 2020 - This label extension of Deltyba (delamanid) represents a new treatment option for children and adolescents with pulmonary ...
3 August 2020 - EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, ...
23 July 2020 - If approved, vosoritide would be the first medicine to treat Achondroplasia in EU. ...
26 June 2020 - EMA CHMP positive opinion paves way for Cosentyx to become a first-line systemic treatment in paediatric psoriasis. ...
1 May 2020 - If approved, Kalydeco (ivacaftor) will be the first and only medicine in Europe to treat the underlying ...
28 March 2020 - AveXis, a Novartis company, today announced that the CHMP of the EMA has adopted a positive ...
10 January 2020 - Sanofi has revealed that the European Commission has expanded the existing label for Toujeo (insulin glargine ...
10 December 2019 - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic ...
29 October 2019 - GlaxoSmithKline today announced that the European Commission has adopted a decision to extend to children five years ...
20 September 2019 - GSK today announced that the EMA's CHMP has issued a positive opinion recommending the use of ...